Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Why Is a Fever an Emergency During DLBCL Treatment?

At a Glance

During DLBCL chemotherapy, a fever of 100.4°F (38°C) or higher may be the first sign of an infection when neutrophils are low. Call your oncology team immediately, follow their threshold, and do not mask the fever with medication.

During DLBCL treatment regimens like R-CHOP, chemotherapy suppresses your bone marrow, temporarily lowering your white blood cell count [1][2]. Because these cells are essential for fighting off bacteria and fungi, an infection can escalate much faster than it would in a healthy person [3]. A fever is often the earliest—and sometimes the only—warning sign [1]. That is why a temperature of 100.4°F (38°C) is treated as a medical emergency requiring prompt assessment and, if an infection is suspected, rapid treatment with antibiotics that cover many likely bacteria [2][4].

What To Do Now: Action Steps

If you currently have a fever of 100.4°F (38°C) or higher, or feel suddenly unwell:

  • Check your temperature using the method approved by your oncology team. (Avoid rectal thermometers, which can cause internal injury and introduce infection).
  • Call your 24-hour oncology hotline immediately. Tell them you are receiving chemotherapy for DLBCL and may be neutropenic. Follow their specific emergency pathway.
  • Do not take acetaminophen, ibuprofen, or aspirin to lower the fever before calling, as this can hide symptoms or cause bleeding complications [5][6]. If you already took one, call anyway and report what you took and when.
  • Do not drive yourself if you feel dizzy or faint.
  • Call emergency services (911) if you have trouble breathing, chest pain, new confusion, severe weakness, blue/gray lips, or cannot keep fluids down.

What is Febrile Neutropenia?

Chemotherapy reduces your levels of neutrophils, the specific white blood cells that act as your primary defense against infection [1]. When your neutrophil count drops below a safe threshold, you have neutropenia. When you develop a fever alongside this low count, the condition is called febrile neutropenia [2].

Normally, an infection causes swelling, redness, pain, or pus. However, because a neutropenic body has a blunted inflammatory response, these classic signs may not appear [7][8]. A fever might be your only clue that an infection is present [1][2]. Importantly, a serious infection can sometimes happen without a fever. Severe chills, a new cough, burning during urination, or redness around a central line port should also prompt an immediate call to your care team [7][1].

The Risk of Sepsis

Without enough neutrophils, bacterial or fungal infections—even from bacteria naturally found on your skin or in your gut—can be harder to control [9][10]. If not treated promptly, this can lead to sepsis [3]. Sepsis is a life-threatening, dysregulated body-wide response to an infection that can cause organ dysfunction and a dangerous drop in blood pressure, known as septic shock [3].

Because clinical deterioration can occur rapidly, sometimes before other obvious signs of infection appear, immediate medical evaluation is critical [11][12]. This urgency is a precaution: prompt medical care is the best way to prevent severe complications, and seeking help quickly does not mean you already have sepsis.

The 100.4°F (38°C) Rule

In medical guidelines, a neutropenic fever is formally defined as a single oral temperature of 101.0°F (38.3°C), or a temperature of 100.4°F (38.0°C) sustained for one hour [2][13].

However, your oncology team’s safety threshold is likely lower and more immediate. If they instruct you to call at the first reading of 100.4°F (38.0°C), you must follow their guidance [14]. Do not wait for your temperature to rise further, and do not wait an hour to see if it stays high [14][1].

When you are evaluated at the clinic or hospital, clinicians will check your vital signs, draw blood for a complete blood count (CBC) and blood cultures, and check for infection sources [2]. If appropriate, they will start broad-spectrum antibiotics—ideally within one hour of your arrival [2][15]. While intravenous (IV) antibiotics in the hospital are common, some carefully selected, low-risk patients may be managed safely with outpatient oral antibiotics based on their medical team’s assessment [16][17].

Why You Should Not Self-Medicate a Fever

You should not take fever-reducing medications for a new fever unless your oncology team explicitly tells you to do so [5][18].

  • Acetaminophen (Tylenol) can artificially lower your temperature, masking the fever and delaying the urgent medical assessment you need [5][18].
  • Ibuprofen, aspirin, and other NSAIDs carry additional risks. Chemotherapy can lower your platelets (the cells that help blood clot) and make your kidneys vulnerable [6][19]. NSAIDs can increase the risk of serious bleeding and kidney damage [6].

Never use fever reducers as a substitute for urgent medical care. A fever during chemotherapy is a time-critical warning where rapid professional assessment saves lives.

Common questions in this guide

Why can a fever become dangerous during DLBCL chemotherapy?
Chemotherapy such as R-CHOP can lower neutrophils, the white blood cells that help control infections. When neutrophils are low, an infection can worsen quickly and may cause few signs besides fever, so prompt medical assessment is needed.
What temperature should prompt a call during DLBCL treatment?
Many oncology teams ask patients to call immediately for a temperature of 100.4°F (38°C) or higher. Some formal definitions use a single oral temperature of 101.0°F (38.3°C) or 100.4°F sustained for an hour, but you should follow your own team's lower or earlier threshold and not wait for the fever to rise.
What should I do if I develop a fever after chemotherapy for DLBCL?
Use the thermometer method approved by your oncology team and call the 24-hour oncology number immediately. Do not take acetaminophen, ibuprofen, or aspirin unless your team tells you to, and call emergency services for trouble breathing, chest pain, confusion, severe weakness, blue or gray lips, or inability to keep fluids down.
Can a serious infection happen without a fever when neutrophils are low?
Yes. Neutropenia can blunt the usual redness, swelling, pain, or pus, and a serious infection may sometimes occur without fever. Severe chills, a new cough, burning with urination, or redness or tenderness around a central-line port should prompt an immediate call to the oncology team.
Why should I avoid Tylenol or ibuprofen before calling about a chemotherapy fever?
Acetaminophen can lower or hide a fever and delay recognition of an urgent problem. Ibuprofen, aspirin, and other NSAIDs may increase bleeding or kidney risks when chemotherapy has lowered platelets or made the kidneys vulnerable, so do not use them instead of urgent medical evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific phone number I should call if I develop a fever after hours or on the weekend?
  2. 2.Which emergency room or urgent care center should I go to, and how should I inform them upon arrival that I am a chemotherapy patient?
  3. 3.What specific thermometer type and measurement method do you recommend I use to monitor my temperature accurately at home?
  4. 4.When is my risk for neutropenia usually the highest after each R-CHOP chemotherapy cycle?
  5. 5.Will I be receiving growth factor injections (like pegfilgrastim) to help my white blood cell counts recover, and how does that affect my fever risk?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Oncologic Emergencies: The Fever With Too Few Neutrophils.

    Long B, Koyfman A

    The Journal of emergency medicine 2019; (57(5)):689-700 doi:10.1016/j.jemermed.2019.08.009.

    PMID: 31635928
  2. 2

    Management of Neutropenic Fever in Persons with Cancer.

    Doyle-Lindrud S

    The Nursing clinics of North America 2025; (60(3)):479-489 doi:10.1016/j.cnur.2024.09.004.

    PMID: 40716808
  3. 3

    Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia.

    Korpelainen S, Intke C, Hämäläinen S, et al.

    Disease markers 2017; (2017()):9805609 doi:10.1155/2017/9805609.

    PMID: 28845081
  4. 4

    Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.

    Pherwani N, Ghayad JM, Holle LM, Karpiuk EL

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2015; (72(8)):619-31 doi:10.2146/ajhp140194.

    PMID: 25825185
  5. 5

    Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.

    Taplitz RA, Kennedy EB, Bow EJ, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(14)):1443-1453 doi:10.1200/JCO.2017.77.6211.

    PMID: 29461916
  6. 6

    Assessment of factors affecting timing of discharge in pediatric cancer patients with febrile neutropenia.

    Üstün C, Aydın B, Kurucu N, et al.

    The Turkish journal of pediatrics 2025; (67(6)):841-854 doi:10.24953/turkjpediatr.2025.5170.

    PMID: 41636196
  7. 7

    [Neutropenia - when is GCSF support indicated?]

    Rehlinghaus M, Rehker P, Che Y, et al.

    Aktuelle Urologie 2024; (55(1)):38-43 doi:10.1055/a-2128-4965.

    PMID: 37607583
  8. 8

    Outcome of severe infections in afebrile neutropenic cancer patients.

    Strojnik K, Mahkovic-Hergouth K, Novakovic BJ, Seruga B

    Radiology and oncology 2016; (50(4)):442-448 doi:10.1515/raon-2016-0011.

    PMID: 27904453
  9. 9

    Febrile neutropenia in the Middle East and North Africa Region: trends, management, and outcomes (2000-2024)-A systematic review.

    El Assaad N, Azzi A, Haddad F, et al.

    IJID regions 2025; (16()):100682 doi:10.1016/j.ijregi.2025.100682.

    PMID: 40703205
  10. 10

    Patterns of Bacterial Isolates and their Resistance to Antibiotics in Patients with Chemotherapy-induced Febrile Neutropenia at a University Hospital.

    Al Saifi SA, Al Adawi B, Burney I

    Oman medical journal 2021; (36(4)):e290 doi:10.5001/omj.2021.87.

    PMID: 34497720
  11. 11

    Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia.

    Intke C, Korpelainen S, Lappalainen M, et al.

    Clinical and experimental medicine 2022; (22(1)):83-93 doi:10.1007/s10238-021-00734-8.

    PMID: 34255216
  12. 12

    Novel biomarkers to identify complicated course of febrile neutropenia in hematological patients receiving intensive chemotherapy.

    Jantunen E, Hämäläinen S, Pulkki K, Juutilainen A

    European journal of haematology 2024; (113(4)):392-399 doi:10.1111/ejh.14264.

    PMID: 38961525
  13. 13

    Antibiotic stewardship in suspected neutropenic fever (ASTERIC trial): a multicentre, type 1 hybrid effectiveness-implementation, stepped-wedge, randomised controlled trial study protocol.

    Rainer TH, Lam RPK, Tsang TC, et al.

    BMJ open 2025; (15(11)):e108010 doi:10.1136/bmjopen-2025-108010.

    PMID: 41290295
  14. 14

    CE: Febrile Neutropenia in the Chemotherapy Patient.

    Foley AM, Hoffman M

    The American journal of nursing 2023; (123(5)):36-42 doi:10.1097/01.NAJ.0000931888.96896.a1.

    PMID: 37021970
  15. 15

    Consensus guidelines for ambulatory care for neutropenic fever.

    Teh JSK, Singh N, Lambros B, et al.

    Internal medicine journal 2025; (55 Suppl 7()):95-114 doi:10.1111/imj.70251.

    PMID: 41521418
  16. 16

    A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.

    Ying FLM, Ping MCY, Tong M, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2018; (26(9)):3039-3045 doi:10.1007/s00520-018-4157-6.

    PMID: 29556814
  17. 17

    The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.

    de la Court JR, Bruns AHW, Roukens AHE, et al.

    Infectious diseases and therapy 2022; (11(6)):2063-2098 doi:10.1007/s40121-022-00700-1.

    PMID: 36229765
  18. 18

    Implementation of a Protocol for Management of Febrile Neutropenia in the Emergency Department at Veteran Health Indiana.

    Melikian L, Bullington S, Harris B, et al.

    Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2023; (40(Suppl 3)):S42-S45 doi:10.12788/fp.0371.

    PMID: 38021097
  19. 19

    Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis.

    Reilly JP, Anderson BJ, Hudock KM, et al.

    Critical care (London, England) 2016; (20(1)):222 doi:10.1186/s13054-016-1398-y.

    PMID: 27431667

This page is for informational purposes only and does not constitute medical advice. It explains why fever during DLBCL chemotherapy needs urgent assessment; follow your oncology team's instructions and contact them immediately about a fever or sudden illness.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.